- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07301255
ENV-294 para el asma moderada a grave: Un estudio de 12 semanas en adultos
Un estudio de fase 2, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 12 semanas para evaluar la eficacia, seguridad y farmacocinética de ENV-294 en participantes adultos con asma de moderada a grave
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).
Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
Descripción general del estudio
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Operations
- Correo electrónico: env-294.clinicaltrials@enveda.com
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35209
- Reclutamiento
- Enveda Investigative Site
-
-
California
-
Los Angeles, California, Estados Unidos, 90025
- Reclutamiento
- Enveda Investigative Site
-
San Jose, California, Estados Unidos, 95117
- Reclutamiento
- Enveda Investigative Site
-
West Hills, California, Estados Unidos, 91307
- Reclutamiento
- Enveda Investigative Site
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos, 80907
- Reclutamiento
- Enveda Investigative Site
-
-
Florida
-
Hialeah, Florida, Estados Unidos, 33012
- Reclutamiento
- Enveda Investigative Site
-
Miami, Florida, Estados Unidos, 33135
- Reclutamiento
- Enveda Investigative Site
-
-
Georgia
-
Albany, Georgia, Estados Unidos, 31707
- Reclutamiento
- Enveda Investigative Site
-
-
Illinois
-
Maryville, Illinois, Estados Unidos, 62062
- Reclutamiento
- Enveda Investigative Site
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Reclutamiento
- Enveda Investigative Site
-
-
Kentucky
-
Owensboro, Kentucky, Estados Unidos, 42301
- Reclutamiento
- Enveda Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Enveda Investigative Site
-
-
Michigan
-
Southfield, Michigan, Estados Unidos, 48075
- Reclutamiento
- Enveda Investigative Site
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63141
- Reclutamiento
- Enveda Investigative Site
-
-
New York
-
The Bronx, New York, Estados Unidos, 10455
- Reclutamiento
- Enveda Investigative Site
-
-
Oregon
-
Clackamas, Oregon, Estados Unidos, 97015
- Reclutamiento
- Enveda Investigative Site
-
Medford, Oregon, Estados Unidos, 97504
- Reclutamiento
- Enveda Investigative Site
-
-
South Carolina
-
North Charleston, South Carolina, Estados Unidos, 29406
- Reclutamiento
- Enveda Investigative Site
-
-
Texas
-
McKinney, Texas, Estados Unidos, 75069
- Reclutamiento
- Enveda Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Reclutamiento
- Enveda Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Able to read, understand, and sign an informed consent form before any study procedures
- Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
- Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
- Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
- Demonstrated bronchodilator reversibility
- ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
- History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care
Exclusion Criteria:
- Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
- History of life-threatening asthma
- Other significant pulmonary disease
- Recent bronchial thermoplasty (within 2 years)
- Uncontrolled current or recurrent concomitant illness
- Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
- Require immunosuppressive medications or frequent systemic corticosteroids
- Current smokers or former smokers with significant smoking history
- Uncontrolled hypertension
- Significant hepatic impairment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ENV-294 Treatment Arm
ENV-294 will be administered to those participants randomized to the treatment arm. |
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks. |
|
Comparador de placebos: Placebo Arm
A placebo will be administered to those participants randomized to the placebo arm. |
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence and Severity of Adverse Events
Periodo de tiempo: From first dose through approximately 16 weeks
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug. |
From first dose through approximately 16 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Loss of Asthma Control Events
Periodo de tiempo: Baseline to Week 12
|
Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria |
Baseline to Week 12
|
|
Time to Loss of Asthma Control
Periodo de tiempo: Baseline to Week 12
|
Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Periodo de tiempo: Baseline to Week 12
|
Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Periodo de tiempo: Baseline to Week 12
|
Change from Baseline in the Asthma Control Questionnaire (ACQ-5) |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Periodo de tiempo: Baseline to Week 12
|
Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ) |
Baseline to Week 12
|
|
Plasma concentration of ENV-294
Periodo de tiempo: Baseline to Week 12
|
Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug. |
Baseline to Week 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ENV-294-211
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .